CH626886A5 - - Google Patents

Download PDF

Info

Publication number
CH626886A5
CH626886A5 CH42377A CH42377A CH626886A5 CH 626886 A5 CH626886 A5 CH 626886A5 CH 42377 A CH42377 A CH 42377A CH 42377 A CH42377 A CH 42377A CH 626886 A5 CH626886 A5 CH 626886A5
Authority
CH
Switzerland
Prior art keywords
acid
compounds
formula
symbols
acid addition
Prior art date
Application number
CH42377A
Other languages
German (de)
English (en)
Inventor
Klaus Peter Bogeso
Anders Stausboll Toft
Original Assignee
Kefalas As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9722860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH626886(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kefalas As filed Critical Kefalas As
Publication of CH626886A5 publication Critical patent/CH626886A5/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CH42377A 1976-01-14 1977-01-13 CH626886A5 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1486/76A GB1526331A (en) 1976-01-14 1976-01-14 Phthalanes

Publications (1)

Publication Number Publication Date
CH626886A5 true CH626886A5 (enExample) 1981-12-15

Family

ID=9722860

Family Applications (3)

Application Number Title Priority Date Filing Date
CH42377A CH626886A5 (enExample) 1976-01-14 1977-01-13
CH357481A CH632258A5 (de) 1976-01-14 1981-06-01 Verfahren zur herstellung von neuen phthalanen.
CH357581A CH632259A5 (de) 1976-01-14 1981-06-01 Verfahren zur herstellung von neuen phthalanen.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CH357481A CH632258A5 (de) 1976-01-14 1981-06-01 Verfahren zur herstellung von neuen phthalanen.
CH357581A CH632259A5 (de) 1976-01-14 1981-06-01 Verfahren zur herstellung von neuen phthalanen.

Country Status (19)

Country Link
US (1) US4136193A (enExample)
JP (1) JPS52105162A (enExample)
AT (1) AT359488B (enExample)
AU (1) AU509445B2 (enExample)
BE (1) BE850401A (enExample)
CA (1) CA1094087A (enExample)
CH (3) CH626886A5 (enExample)
DE (1) DE2657013C2 (enExample)
DK (1) DK143275C (enExample)
ES (1) ES454980A1 (enExample)
FI (1) FI63754C (enExample)
FR (1) FR2338271A1 (enExample)
GB (1) GB1526331A (enExample)
IE (1) IE44055B1 (enExample)
NL (2) NL192451C (enExample)
NO (2) NO147243C (enExample)
NZ (1) NZ183001A (enExample)
SE (1) SE429551B (enExample)
ZA (1) ZA7757B (enExample)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
PT759299E (pt) * 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
DK1015416T3 (da) 1997-07-08 2001-11-05 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
JP3813820B2 (ja) 1997-11-11 2006-08-23 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
ATE230738T1 (de) 1998-10-20 2003-01-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
KR20010081071A (ko) 1998-12-08 2001-08-25 피터슨 존 메이달 벤조푸란 유도체, 그것들의 제조 및 사용
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
TR200101796T2 (tr) 1998-12-23 2001-11-21 H. Lundbeck A/S 5-Siyanofitalitin preparasyonuna yönelik metot
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
PL198024B1 (pl) * 1999-04-14 2008-05-30 Lundbeck & Co As H Sposób wytwarzania citalopramu, związki pośrednie i ich zastosowanie do wytwarzania citalopramu
ITMI991579A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991486A1 (it) * 1999-07-06 2001-01-06 Vis Farmaceutici S P A Processo per la sintesi di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
PT1298124E (pt) 1999-10-25 2007-05-31 Lundbeck & Co As H Método para a preparação de citalopram
ES2169709A1 (es) * 1999-10-25 2002-07-01 Lundbeck & Co As H Metodo para la preparacion de citalopram
US6310222B1 (en) * 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
CN1398263A (zh) * 1999-12-28 2003-02-19 H·隆德贝克有限公司 制备西酞普兰的方法
PL198803B1 (pl) * 1999-12-30 2008-07-31 Lundbeck & Co As H Sposób wytwarzania 5-cyjano-3H-izobenzofuran-1-onu
EP1254129B1 (en) * 2000-01-14 2003-10-22 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
US6433196B1 (en) * 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
NL1017415C1 (nl) * 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
IES20010143A2 (en) * 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
JP2003527387A (ja) * 2000-03-13 2003-09-16 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
CN1427835A (zh) * 2000-03-13 2003-07-02 H·隆德贝克有限公司 5-取代的1-(4-氟苯基)-1,3-二氢异苯并呋喃的分步烷基化
DK1265882T3 (da) 2000-03-14 2004-06-01 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
KR20020080483A (ko) * 2000-03-16 2002-10-23 하. 룬트벡 아크티에 셀스카브 5-시아노-1-(4-플루오로페닐)-1,3-디히드로이소벤조푸란의제조 방법
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
AR032455A1 (es) * 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
KR100821912B1 (ko) * 2000-05-12 2008-04-16 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
AU2001272368A1 (en) * 2000-07-06 2002-01-21 H. Lundbeck, A/S Method for the preparation of citalopram
CZ2003396A3 (cs) * 2000-07-21 2003-05-14 H. Lundbeck A/S Inhibitory transportu glycinu
IES20010693A2 (en) 2000-08-10 2002-07-10 Lundbeck & Co As H Pharmaceutical composition containing citalopram
IL144817A0 (en) * 2000-08-18 2002-06-30 Lundbeck & Co As H Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
IT1319686B1 (it) * 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
SG167655A1 (en) 2000-12-22 2011-01-28 Lundbeck & Co As H Method for the preparation of pure citalopram
HRP20020005A2 (en) * 2000-12-28 2003-04-30 Lundbeck & Co As H Process for the preparation of pure citalopram
DE10164725B4 (de) * 2000-12-28 2004-08-26 H. Lundbeck A/S Verfahren zur Herstellung von gereinigtem Citalopram
DE10112828C1 (de) * 2000-12-28 2002-11-21 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
CA2435925A1 (en) 2001-01-30 2002-08-08 Orion Corporation Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
JP2004529883A (ja) * 2001-02-22 2004-09-30 ナトコ ファーマ リミテッド シタロプラムの調製方法
GB0105627D0 (en) * 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
WO2002072565A1 (en) * 2001-03-09 2002-09-19 Ranbaxy Laboratories Limited Process for the preparation of citalopram
MXPA03008777A (es) * 2001-05-01 2004-02-12 Lundbeck & Co As H El uso de escitalopram enantiomericamente puro.
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IN192057B (enExample) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
AU2002355624B2 (en) 2001-07-31 2006-02-02 H. Lundbeck A/S Crystalline composition containing escitalopram
EP1288211A1 (en) * 2001-08-28 2003-03-05 Sekhsaria Chemicals Ltd. Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US6967259B2 (en) * 2001-09-24 2005-11-22 Pharmachem Technologies Limited Process for the preparation of Citalopram intermediate
EP1434763B1 (en) * 2001-10-12 2018-01-17 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1a antagonists
IN192863B (enExample) * 2001-11-13 2004-05-22 Ranbaxy Lab Ltd
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
WO2003057132A2 (en) * 2002-01-07 2003-07-17 Sun Pharmaceutical Industries Limited Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
GB2387844B (en) * 2002-02-27 2005-05-11 Matrix Lab Ltd Separation of impurities from a crude mixture of citalopram
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
DE60334785D1 (de) * 2002-03-27 2010-12-16 Bando Chemical Ind Neues 1,3,5-tris(arylamino)benzol
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
AR040970A1 (es) 2002-08-12 2005-04-27 Lundbeck & Co As H Metodo para la separacion de intermediarios que pueden ser utilizados para la preparacion de escitalopram
AU2002330730A1 (en) * 2002-08-14 2004-03-03 Natco Pharma Limited Process for the preparation of high purity citalopram and its pharmaceutically acceptable salts
GB2385051B (en) * 2002-08-29 2003-12-24 Max India Ltd Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
BR0317623A (pt) * 2002-12-23 2005-11-29 Lundbeck & Co As H Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
AU2003242990A1 (en) * 2003-01-17 2004-08-13 Pulla Reddy Muddasani Processes for the preparation of escitalopram and its precursor
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
ITMI20030479A1 (it) * 2003-03-13 2004-09-14 Adorkem Technology S P A Procedimento per la preparazione di un ciano-isobenzofurano.
EP1486492A3 (en) * 2003-06-10 2005-02-23 Sun Pharmaceuticals Industries Ltd. A process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran.
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
ITFI20030202A1 (it) * 2003-07-28 2005-01-29 Synteco Spa Processo per la preparazione di derivati del
AU2004283196B2 (en) * 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
BR0318581A (pt) * 2003-10-28 2006-10-10 Wockhardt Ltd processo melhorando para fabriacação de bromidrato de citalopram
DE60300502T2 (de) * 2003-10-28 2006-02-23 Adorkem Technology S.P.A., Costa Volpino Verfahren zur Herstellung von Citalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
EP2343073A3 (en) 2003-12-11 2011-10-12 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20080119662A1 (en) * 2004-02-16 2008-05-22 Jubilant Organosys Limted One Spot Synthesis of Citalopram from 5-Cyanophthalide
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) * 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1797060A2 (en) 2004-08-23 2007-06-20 Sun Pharmaceutical Industries Limited "process for preparation of citalopram and enantiomers"
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
WO2006103550A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Processes for the preparation of citalopram and its intermediate 5-aminophthalide
AU2006239922A1 (en) 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
WO2006116150A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
GT200600158A (es) * 2005-04-22 2006-11-28 Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
EP2317316A3 (en) 2005-07-08 2011-06-15 Braincells, Inc. Methods for identifying agent and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
KR101523776B1 (ko) * 2005-07-19 2015-05-28 아제반 파마슈티칼스, 인코퍼레이티드 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1951726A2 (en) * 2005-11-14 2008-08-06 H.Lundbeck A/S Method for the preparation of escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス,インコーポレイティド 4−アシルアミノピリジン誘導体を含む組み合わせ
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
JP4927497B2 (ja) * 2006-10-25 2012-05-09 株式会社シスコ 無湿乾燥用ホッパー装置
CN100457747C (zh) * 2006-11-21 2009-02-04 浙江大学 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
ATE534639T1 (de) * 2007-04-23 2011-12-15 Synthon Bv Verfahren zur lösung von citalopram
WO2008142379A2 (en) * 2007-05-18 2008-11-27 Cipla Limited Process for the preparation of escitalopram via desmethylcitalopram, optical resolution and methylation of the s-isomer
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US8022232B2 (en) * 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20100087664A1 (en) * 2008-10-07 2010-04-08 Ravindra Vedantham Preparation of citalopram and salts thereof
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101859409B1 (ko) 2009-10-23 2018-05-18 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로[3,4-c]피롤
ES2662350T3 (es) 2010-07-01 2018-04-06 Azevan Pharmaceuticals, Inc. Procedimientos para el tratamiento del trastorno por estrés postraumático
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
WO2013110313A1 (en) * 2012-01-23 2013-08-01 H. Lundbeck A/S Selective allosteric modulators of the serotonin transporter
US9802925B2 (en) 2014-03-28 2017-10-31 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
PT3426251T (pt) * 2016-03-10 2022-07-27 Janssen Pharmaceutica Nv Métodos de tratamento da depressão utilizando antagonistas dos recetores de orexina-2
MX2020002762A (es) 2017-09-15 2020-09-17 Azevan Pharmaceuticals Inc Composiciones y métodos para tratar una lesión cerebral.
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (enExample) * 1965-03-18

Also Published As

Publication number Publication date
NL192451B (nl) 1997-04-01
NL970031I1 (nl) 1997-10-01
JPS52105162A (en) 1977-09-03
FR2338271B1 (enExample) 1982-11-05
NL192451C (nl) 1997-08-04
NL970031I2 (nl) 1997-10-01
BE850401A (fr) 1977-07-14
SE429551B (sv) 1983-09-12
DK143275B (da) 1981-08-03
NO770109L (no) 1977-07-15
NL7700244A (nl) 1977-07-18
ATA947276A (de) 1980-04-15
CH632258A5 (de) 1982-09-30
AT359488B (de) 1980-11-10
IE44055B1 (en) 1981-07-29
CH632259A5 (de) 1982-09-30
NZ183001A (en) 1978-06-02
DE2657013C2 (de) 1985-11-14
ES454980A1 (es) 1978-04-01
CA1094087A (en) 1981-01-20
NO147243C (no) 1983-03-02
FI770073A7 (enExample) 1977-07-15
IE44055L (en) 1977-07-14
DE2657013A1 (de) 1977-07-28
AU2107377A (en) 1978-07-13
FR2338271A1 (fr) 1977-08-12
FI63754C (fi) 1983-08-10
NO1996001I1 (no) 1996-01-05
US4136193A (en) 1979-01-23
DK143275C (da) 1982-01-18
JPS6135986B2 (enExample) 1986-08-15
NO147243B (no) 1982-11-22
AU509445B2 (en) 1980-05-15
SE7614201L (sv) 1977-07-15
FI63754B (fi) 1983-04-29
ZA7757B (en) 1977-11-30
GB1526331A (en) 1978-09-27
DK13177A (da) 1977-07-15

Similar Documents

Publication Publication Date Title
CH626886A5 (enExample)
DE68921672T2 (de) Enantiomere und ihre Trennung.
DE2500110A1 (de) 3-aryloxy-3-phenylpropylamine und verfahren zu ihrer herstellung
DE1643262C3 (de) i-Phenoxy^-hydroxy-S-alklyaminopropane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE1543715A1 (de) Verfahren zur Herstellung von basischen Derivaten von Phthalanen und Isochromanen
DE2727144C3 (de) Verwendung bestimmter Chinolinderivate
DE3204960A1 (de) Corynanthein-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2451474A1 (de) Neue phenylpropenylaminderivate
DE2507429C2 (de) Aminosäureester, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2638850C2 (de) 2-Amino-N↑1↑-(1-phenyl-2-methyl-2-propyl)-propionsäureamide, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE1915230A1 (de) Hydroxyphenylalkylaminderivate und Verfahren zu deren Herstellung
DE2621535A1 (de) Phenyl-piperidinderivate und deren salze, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
CH623562A5 (enExample)
AT360001B (de) Verfahren zur herstellung von neuen phthalan- -derivaten und ihren pharmazeutisch ver- traeglichen saeureadditionssalzen
DE1922280C3 (de) l-Methyl-5-(3'-dimethylaminopropyliden)-5Hdibenzo [a,d] -cyelohepten-N- oxid und dessen Säureadditionssalze, sowie Verfahren zu deren Herstellung und diese Verbindungen enthaltende Präparate
AT360002B (de) Verfahren zur herstellung von neuen phthalan- -derivaten und ihren pharmazeutisch ver- traeglichen saeureadditionssalzen
DE2522218B2 (de) Zusammensetzung für die Human- oder Veterinärmedizin, Methylaminderivate und Verfahren zu deren Herstellung
DE2348577A1 (de) L-amino-4-phenyltetralin-derivate und diese enthaltende pharmazeutische zubereitung
DE2738131A1 (de) Aminoketone, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE3640829A1 (de) Neue 1-aryloxy-3-amino-2-propanole, ihre herstellung und verwendung
DE2204989C3 (de) 2-Phenyl-3-(beta-dlmethylaminopropionyl)benzoturan und dessen pharmakologisch verträgliche Säureadditionssalze sowie diese Verbindungen enthaltende Arzneimittel
DE3706399A1 (de) Mittel mit antidepressiver wirkung
DE2227842C3 (de) Diphenylcyclopentane und diese enthaltende Arzneimittel
CH677669A5 (enExample)
DE2638849A1 (de) Aminosaeureester, verfahren zu ihrer herstellung und sie enthaltende arzneimittel

Legal Events

Date Code Title Description
PFA Name/firm changed

Owner name: H. LUNDBECK A/S

PUE Assignment

Owner name: H. LUNDBECK & CO., A/S

SPCF Supplementary protection certificate filed

Free format text: IKS 49970, 901214

SPCG Supplementary protection certificate granted

Free format text: IKS 49970/901214, 951024, EXPIRES:20020112

PL Patent ceased